Solaris Vaccines has cracked a fundamental problem in infectious disease, and the US government is already paying attention.
Every major pandemic of the past century has exposed the same weakness in global health infrastructure: we cannot build effective vaccines fast enough, safely enough, or cheaply enough. Solaris Vaccines, a Colorado-based biotech startup, believes the answer has been hiding in plain sight and it involves nothing more exotic than UV light and vitamin B2.
The company's flagship platform, SolaVAXTM, uses a photochemical process already trusted in blood banks worldwide since 2008 to neutralize dangerous pathogens—viruses, bacteria, parasites, fungi—while leaving their immune-stimulating proteins perfectly intact. The result: Vaccines and therapeutic antibodies that trigger stronger, more durable protection, with none of the toxicity concerns that have historically shadowed the field and fueled public skepticism.
What Makes SolaVAX Different
Traditional vaccine manufacturing relies on heat, acid, or toxic chemicals to kill pathogens before using them as the basis for a vaccine. These methods are blunt instruments in that hey often damage the very antigens that teach the immune system how to fight back. The resulting vaccines tend to be less protective, require booster doses, and raise legitimate questions about residual chemical safety.
SolaVAX works differently. By using UV light alongside vitamin B2, it disables a pathogen's ability to replicate without touching its surface proteins. Those proteins remain in their natural shape, presenting the immune system with an authentic target. In animal studies with SARS-CoV-2, SolaVAX-generated therapies reduced nasal and lung viral burden by more than 95% and prevented the weight loss typically associated with severe infection.
From Lab to Industrial Scale
Proof-of-concept is one thing. Scale is another. Solaris has developed SolaFLOW, a compact industrial device roughly the size of a countertop microwave and capable of continuously processing thousands of liters of pathogen-containing fluid. Unlike existing alternatives, it is purpose-built for this application, fits inside biosafety containment labs, and works with standard upstream and downstream bioprocessing equipment. There is currently nothing else like it on the market.
This hardware business gives Solaris an early, capital-efficient path to revenue, selling instruments and consumables to pharmaceutical companies, biotech firms, and life science reagent producers, while its internal pipeline of vaccine and antibody candidates matures toward licensing deals with larger partners.
A Business Built for Multiple Outcomes
Solaris is pursuing a deliberately diversified strategy. Hardware sales generate near-term cash flow. Internal vaccine and therapeutic candidates, validated with government funding, become licensing assets. And the architecture of the business—hardware on one side, biologics on the other—creates the option to spin out either division independently, maximizing value for investors regardless of how the market evolves.
The company has already demonstrated it can attract non-dilutive capital at scale. It has received grants and contracts totaling more than $2.8 million from the NIH and the US Department of Defense, with additional proposals in progress. This government backing serves as both a validation signal and a funding cushion, reducing the burden on private investors while advancing the science.
Leadership
Solaris Vaccines is more than a biotech startup; it is a shift in how we protect humanity. With the power of UV light and vitamin B2, we are closing the gap in global health infrastructure and building a future where the next pandemic meets a truly smarter defense.